A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:7/2/2016
Start Date:February 2016
Contact:Paul Nemeth, Ph.D.
Email:paul@churchillpharma.com
Phone:610-382-5613

Use our guide to learn which trials are right for you!

A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to evaluate the serum testosterone levels in patients with
Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as
Compared to Abiraterone Acetate

This is 12-week, open-label study of abiraterone acetate in at least 50 patients with
metastatic castration-resistant prostate cancer. The primary endpoint is total testosterone
at pharmacokinetic steady-state. Additional secondary endpoints include safety assessments,
PSA and pharmacokinetic measurements

Inclusion Criteria:

1. Written informed consent obtained prior to any study-related procedure being
performed

2. Male subjects at least 18 years of age or older at time of consent

3. Pathologically confirmed adenocarcinoma of the prostate

4. Ongoing therapy with a GnRH agonist or antagonist AND serum testosterone level <50
ng/dL at screening

5. Metastatic disease documented by computed tomography (CT)/ magnetic resonance imaging
(MRI) or bone scan. Imaging obtained within 42 days prior to the start of study
medication will be accepted.

6. Meeting disease progression according to the recommendations of the prostate cancer
working group 2 by one of the following criteria:

- Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement
of at least 2 ng/mL,

- Imaging progression (CT/MRI) by RECIST criteria

- Nuclear scan progression by new lesion.

7. Discontinuation of flutamide or nilutamide, and other anti-androgens at least 4 weeks
prior to the start of study medication; discontinuation of bicalutamide at least 6
weeks prior to start of study medication.

8. Discontinuation of Radiotherapy > 4 weeks prior to start of study medication.

9. ECOG performance status of 0-1 at screening

10. Screening blood counts of the following:

- Absolute neutrophil count > 1500/µL

- Platelets > 100,000/µL

- Hemoglobin > 9 g/dL

11. Screening chemistry values of the following:

- ALT and AST < 2.5 x ULN

- Total bilirubin < 1.5 x ULN

- Creatinine< 1.5 x ULN

- Albumin > 3.0 g/dL

12. Potassium > 3.5 mmol/L

13. Life expectancy of at least 6 months at screening

14. Subject is willing and able to comply with all protocol requirements assessments

15. Agrees to protocol-defined use of effective contraception.

Exclusion Criteria:

1. History of impaired pituitary or adrenal gland function

2. Prior therapy with abiraterone acetate, orteronel, ketoconazole or any other CYP17
inhibitor

3. Prior therapy with enzalutamide

4. Prior use of experimental androgen receptor antagonist

5. Previous exposure to Ra-223:Xofigo

6. Previous chemotherapy

7. Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start
of study medication. Patients who are on a stable dose of these medications for at
least 30 days at the time of starting study drug are eligible.

8. Therapy with estrogen within 30 days prior to the start of study medication

9. Use of systemic glucocorticoids equivalent to > 10 mg of prednisone daily; patients
who have discontinued or have reduced dose to < 10 mg prednisone within 14 days prior
to the start of study medication will be eligible

10. Prior use of any herbal products that may decrease PSA levels (eg., saw palmetto)
within 30 days of start of study medication

11. Known metastases to the brain or CNS involvement

12. History of other malignancy within the previous 2 years

13. Major surgery within 30 days prior to the start of study medication

14. Blood transfusion within 30 days of screening

15. Serious, persistent infection within 14 days of the start of study medication

16. Persistent pain that requires the use of a narcotic analgesic

17. Known gastrointestinal disease or condition that may impair absorption

18. Treatment with any investigational drug within 4 weeks prior to Day -1 of the study.

19. Known history of human immunodeficiency virus (HIV) or seropositive test for
hepatitis C virus or hepatitis B virus

20. Have poorly controlled diabetes.

21. Uncontrolled hypertension

22. History of New York Heart Association (NYHA) class III or IV heart failure

23. Serious concurrent illness, including psychiatric illness, that would interfere with
study participation

24. Inability to swallow tablets whole

25. Known hypersensitivity to any excipients in study medications

26. Moderate to severe hepatic impairment (Child-Pugh Classes B and C)
We found this trial at
17
sites
Towson, Maryland 21204
Principal Investigator: Richard Levin, MD
?
mi
from
Towson, MD
Click here to add this to my saved trials
Brandenton, Florida 34205
Principal Investigator: Alan Miller, MD
Phone: 941-792-0340
?
mi
from
Brandenton, FL
Click here to add this to my saved trials
Brooklyn, New York 11215
Principal Investigator: Ivan Grunberger, MD
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Cary, North Carolina 27511
?
mi
from
Cary, NC
Click here to add this to my saved trials
Dallas, Texas 75231
Principal Investigator: James Cochran, MD
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Englewood, Colorado 80113
Principal Investigator: Barrett Cowan, MD
?
mi
from
Englewood, CO
Click here to add this to my saved trials
Laguna Hills, California 92653
Principal Investigator: Neyssan Tebyani, MD
?
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Lincoln, Nebraska 68516
Principal Investigator: Jonathan Henning, MD
Phone: 402-489-8888
?
mi
from
Lincoln, NE
Click here to add this to my saved trials
Los Angeles, California 90048
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Omaha, Nebraska 68130
Principal Investigator: Luke Nordquist, MD
Phone: 402-991-8468
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Raleigh, North Carolina 27612
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
San Bernardino, California 92404
Principal Investigator: Franklin Chu, MD
Phone: 909-881-0555
?
mi
from
San Bernardino, CA
Click here to add this to my saved trials
Torrance, California 90505
?
mi
from
Torrance, CA
Click here to add this to my saved trials
Virginia Beach, Virginia 23462
Principal Investigator: Robert Given, MD
Phone: 757-452-3462
?
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
West Des Moines, Iowa 50266
?
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Whittier, California 90603
Principal Investigator: Eric Cheung, MD
Phone: 562-693-4477
?
mi
from
Whittier, CA
Click here to add this to my saved trials
Wichita, Kansas 67226
Principal Investigator: Timothy Richardson, MD
Phone: 316-636-6100
?
mi
from
Wichita, KS
Click here to add this to my saved trials